Resources
75 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/25/2022 (updated 4/26/2024)
A guidebook from the Substance Abuse and Mental Health Services Administration describes various methods of adapting evidence-based practices for substance use disorder (SUD) to meet the needs of populations who experience barriers in receiving behavioral health services due to a variety of factors including race, ethnicity, geography, income, sexual orientation, and disability.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/26/2021 (updated 4/10/2024)
The Evidence-Based Resource Guide Series is a comprehensive set of modules with resources to improve health outcomes for people at risk for, with, or recovering from mental and/or substance use disorders. It is designed for practitioners, administrators, community leaders, and others considering an intervention for their organization or community.
Posted 3/2/2021 (updated 4/4/2024)
This session will walk through the strategic plan template provided by JBS International in the Grantee Onboarding Packet for HRSA RCORP-Planning Grantees. During this workshop style webinar, facilitators will walk grantees through the template section by section, discussing the required elements and providing examples of each section. Grantees will learn how to use their data to determine problem statements, goals, objectives, and outcomes for their strategic plan as well as how to include metrics to successfully track their progress.
Posted 2/17/2021 (updated 4/4/2024)
New Series of Advisories on Substance Use Disorder Treatment.
Posted 10/26/2021 (updated 4/3/2024)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 10/14/2021 (updated 4/3/2024)
Representatives from the JBS/HRSA evaluation team presented information on Performance Improvement Measurement System deliverables and answer grantee questions.
Rebecca Schachtner, PhD, JBS International
Posted 10/14/2021 (updated 4/3/2024)
Presenters reviewed resources available to rural grantees through their respective agencies.
Posted 11/18/2020 (updated 4/3/2024)
Healthcare provider burnout can lead to substance use disorder (SUD) and significant consequences for the individual, patients, and healthcare institutions. This webinar explored healthcare provider burnout, the scope of SUD in the medical community, and current pathways to recovery.